Day: August 29, 2024

Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference

AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci Compact SMART genome editing tools that fit within delivery technologies constrained by cargo size may enable broad disease targeting EMERYVILLE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a poster titled “Unlocking the Therapeutic Potential of Compact SMART Nucleases through Ancestral Reconstruction, Structure-Guided Engineering, and Generative AI” at the tenth meeting on Genome Engineering: CRISPR Frontiers at Cold Spring Harbor Laboratory, hosted in Cold Spring Harbor, NY from August 27-31,...

Continue reading

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash. The claim method allows for MN-166 (ibudilast) to be...

Continue reading

Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection. The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000® vaccine was shown to be effective in protecting against mpox virus exposure. ACAM2000® is a single-dose vaccine administered percutaneously via a bifurcated needle that is dipped into the vaccine solution and the skin is pricked several times in the upper arm with a droplet of the vaccine. The...

Continue reading

LNG Energy Group Reports Second Quarter 2024 Financial and Operating Results

Key Highlights: 2nd Quarter operating netbacks of $5.08/Mcf natural gas and $51.58/bbl condensate ($29.74/boe). Conditionally awarded two Productive Participation Contracts to develop and produce hydrocarbons in Venezuela. Creation of new Oilfield Services Division to capitalize on LNG Energy Group’s unique vertical integration. Repayment of $11.8 million in senior secured bank indebtedness to date. TORONTO, Aug. 29, 2024 (GLOBE NEWSWIRE) — LNG Energy Group Corp. (TSXV: LNGE) (TSXV: LNGE.WT) (OTCQB: LNGNF) (FWB: E26) (the “Corporation” or “LNG Energy Group”) is pleased to announce its financial and operating results for the quarter ended on June 30, 2024. All dollar amounts are expressed in United States dollars, except where otherwise indicated. “In Q2 2024, we continued our work on growing the production of our Colombian...

Continue reading

Clip Money Inc. Reports Second Quarter 2024 Results

TORONTO, Aug. 29, 2024 (GLOBE NEWSWIRE) — Clip Money Inc. (TSXV:CLIP) (OTCQB:CLPMF) (“Clip Money” or the “Company”), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce its financial results for the three months ended June 30, 2024. Second Quarter 2024 Highlights Revenue for Q2 2024 was $387,955, compared to $44,907 in Q2 2023, which equates to 764% growth year-over-year (“YoY”), and 30% growth quarter-over-quarter (“QoQ”). Revenue growth continues to materially outpace changes in Costs of Good Sold (“COGS”). On a YoY basis, COGS were up only 20%. Furthermore, COGS were down 4% on a QoQ basis despite an increase in revenue. YoY revenue growth for Q2 2024 was driven by a 458% increase in deposit users, and a 168% increase in average revenue per user. New user growth was driven...

Continue reading

CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed

NEW YORK, USA and SEOUL, Korea, Aug. 29, 2024 (GLOBE NEWSWIRE) — Mountain Crest Acquisition Corp. V, a Delaware corporation formed as a special purpose acquisition company (“Mountain Crest V”), with its common stock publicly traded on The Nasdaq Stock Market under the trading symbol “MCAG” and CUBEBIO Co., Ltd., a corporation (“chusik hoesa”) organized under the laws of Korea (“CUBEBIO”), which has an innovative technology that diagnoses cancer at an early stage using urine, today announced that the parties entered into a definitive business combination agreement, dated August 29, 2024 (the “BCA”) for a proposed business combination transaction through which CUBEBIO plans to become a public company with its securities listed on The Nasdaq Stock Market. Mountain Crest V is the fifth vehicle in the Mountain Crest family of SPACs,...

Continue reading

Evolution Petroleum Schedules Fiscal Year End 2024 Earnings Release and Conference Call

HOUSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) — Evolution Petroleum Corporation (NYSE American: EPM) (“Evolution” or the “Company”) today announced that it plans to release its fourth quarter and fiscal year-end 2024 financial and operating results on Tuesday, September 10, 2024, after the market closes. Additionally, Kelly Loyd, President and Chief Executive Officer, Ryan Stash, Senior Vice President, Chief Financial Officer, and Treasurer, and Mark Bunch, Chief Operating Officer, will review the results on a conference call at 10:00 a.m. Central Time on Wednesday, September 11, 2024. Conference Call and Webcast Details Date: Wednesday, September 11, 2024Time: 10:00 a.m. Central TimeDial-In: (844) 481-2813International Dial-In: (412) 317-0677Note: Dial-in participants should ask to join the Evolution Petroleum...

Continue reading

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues). Both quarters (Q1 and Q2 of 2024) ended with positive EBITDAs and profit from operations and represents InterCure’s 16th and 17th consecutive quarter of profitability2. Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to its Southern Facility located at Kibbutz Nir Oz. To date, InterCure has already received tens of millions of NIS as partial advance payments from the Israeli authorities. Announced Expansion of its strategic partnership with Cookies™ to Germany and expects to launch first Cookies...

Continue reading

Solar Alliance reports profitable first half of 2024

Company remains focused on larger, higher margin commercial solar projects and targeting full year profitability TORONTO and KNOXVILLE, Tenn., Aug. 29, 2024 (GLOBE NEWSWIRE) — Solar Alliance Energy Inc. (‘Solar Alliance’ or the ‘Company’) (TSX-V: SOLR, OTC: SAENF), a leading solar energy solutions provider focused on the commercial and utility solar sectors, announces it has filed its unaudited financial results for the for the three- and six-month period ended June 30, 2024. The Company’s Financial Statements and related Management’s Discussion and Analysis are available under the Company’s profile at www.sedarplus.ca and on the Solar Alliance website at www.solaralliance.com.    “The Solar Alliance team experienced a busy second quarter as we worked through the installation of several larger projects in our pipeline. Our purposeful...

Continue reading

ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2024 Q2 FINANCIAL RESULTS AND NEW OPPORTUNITIES

Greenville, South Carolina, Aug. 29, 2024 (GLOBE NEWSWIRE) — ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) will host a conference call at 4:45pm Eastern time, Wednesday, September 4, 2024 to review the Company’s Q2 financial results for the period ending June 30, 2024. The Company will also discuss new opportunities as a result of the transaction with Any Lab Tests Now and creation of CRESSO Brands, LLC., as announced August 20, 2024. The dial-in number for the conference call is as follows: Canada / USA Toll Free 1-844-763-8274International Toll +1-647-484-8814 Callers should dial in 5 – 10 min prior to the scheduled start time and ask to join the ARCpoint call: ARCpoint President and CEO, John Constantine commented “Over the past year and a half, we have made tremendous progress in broadening our business and expanding...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.